hotspot -WSS

hotspot

author：explore 2025-10-02 22:24:59 - browse：9657

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Celebrate National Dole Whip Day for 3 days this week at Disney

knowledge

WSS

Covid vaccines: Private market messier than government rollout

Health tech startups drop sharply from 2021 highs

Did you have Obamacare on your GOP debate bingo card?

Celebrate National Dole Whip Day for 3 days this week at Disney

WHO recommends dropping component of many flu vaccines

Shingles, which affected Dianne Feinstein, is on the rise

focus

hotspot

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

Medicare drug price negotiation program allowed for now

Dobbs anniversary: the lost opportunity of abortion as health care

Health tech startups drop sharply from 2021 highs

Sports medicine is finally prioritizing gender equality

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

23andMe had bad news about my health. I wish a person had delivered it

FDA seeks to regulate lab

Activists slam private health insurers over coverage restrictions

Kaiser Permanente unions announce official strike date

explore

Ionis has late

Ionis has late

Researchers use wearables data and AI to predict preterm birth risk

Listen: Who gets the credit for GLP

FDA seeks to regulate lab

Kaiser Permanente unions announce official strike date

hotspot

focus

knowledge

focus